Japan poised to put 70% price lid on biosimilars, cap generics at 50% of reference drug

Japan is considering capping the price of biosimilars at 70% of the reference drug, while lowering the price cap on generics from 60% to 50% of the price for the drugs they copy. The government has pushed generics as a way to lower drug spending but now appears poised to reduce those drug prices further as the economy continues to stall, putting pressure on the national health system, the Kyodo News reports. More from FiercePharmaAsia

Suggested Articles

Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GSK's Zejula for the patient group.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.